Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial Dr Helena M Earl, MBBS, Louise Hiller, PhD, Prof Janet A Dunn, PhD, Clare Blenkinsop, Louise Grybowicz, BSc, Anne-Laure Vallier, MSc, Jean Abraham, MBBS, Jeremy Thomas, MBBS, Elena Provenzano, MD, Luke Hughes-Davies, MBBCh, Ioannis Gounaris, MD, Karen McAdam, MBBS, Stephen Chan, MBBCh, Rizvana Ahmad, MBBS, Tamas Hickish, MBBS, Stephen Houston, MBBS, Daniel Rea, PhD, Prof John Bartlett, PhD, Prof Carlos Caldas, MD, Prof David A Cameron, MD, Larry Hayward, MBChB The Lancet Oncology Volume 16, Issue 6, Pages (June 2015) DOI: /S (15) Copyright © 2015 Earl et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions Terms and Conditions
Figure 1 The Lancet Oncology , DOI: ( /S (15) ) Copyright © 2015 Earl et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions Terms and Conditions
Figure 2 The Lancet Oncology , DOI: ( /S (15) ) Copyright © 2015 Earl et al. Open Access article distributed under the terms of CC BY-NC-ND Terms and Conditions Terms and Conditions